630 West Germantown Pike
Suite 215
Plymouth Meeting, PA 19462
United States
484 539 9800
https://www.harmonybiosciences.com
Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 246
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Mr. Jeffrey S. Aronin | Founder & Non-Executive Chairman | 185,67k | N/D | 1968 |
Dr. Jeffrey M. Dayno M.D. | President, CEO & Director | 1,26M | N/D | 1957 |
Mr. Jeffrey Dierks M.B.A. | Executive VP & Chief Commercial Officer | 830,75k | N/D | 1972 |
Mr. Andrew Serafin J.D., M.B.A. | Executive VP & Chief Strategy Officer | 647,42k | N/D | 1975 |
Dr. Kumar Budur M.D., M.S. | Executive VP & Chief Medical Officer | 760,81k | N/D | N/D |
Mr. David Bradshaw | Head of Technical Operations | N/D | N/D | N/D |
Luis Sanay | Head of Investor Relations | N/D | N/D | N/D |
Mr. Christian Ulrich | General Counsel & Corporate Secretary | N/D | N/D | N/D |
Ms. Tricia Glover | Chief Compliance Officer | N/D | N/D | N/D |
Ms. Audrey Murphy SPHR | Vice Presidet of Human Resources | N/D | N/D | N/D |
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.
L'ISS Governance QualityScore di Harmony Biosciences Holdings, Inc. al 1 maggio 2024 è 8. I criteri di valutazione fondamentali sono revisione: 7; Consiglio di Amministrazione: 9; diritti degli azionisti: 8; retribuzione: 8.